NCT03907488 2026-06-01Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin LymphomaNational Cancer Institute (NCI)Phase 3 Active not recruiting994 enrolled 11 charts 1 FDA